New pill could help men regrow hair

NCT ID NCT06724614

Ongoing Disease control Sponsor: Veradermics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months. The goal is to see if the drug safely increases hair count and improves perceived hair growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGA ANDROGENETIC ALOPECIA MALE PATTERN BALDNESS

Contacts and locations

Locations

Site 01

Spokane, Washington, 99202, United States
Site 02

Fremont, California, 94538, United States
Site 03

Tampa, Florida, 33613, United States
Site 04

Nashville, Tennessee, 37215, United States
Site 05

Castle Rock, Colorado, 80109, United States
Site 06

New Brighton, Minnesota, 55112, United States
Site 07

Fountain Valley, California, 92728, United States
Site 08

Broomall, Pennsylvania, 19073, United States
Site 09

Knoxville, Tennessee, 37909, United States
Site 10

Plymouth Meeting, Pennsylvania, 19462, United States
Site 11

Columbus, Ohio, 43215, United States
Site 12

Metairie, Louisiana, 70006, United States
Site 13

Covington, Louisiana, 70433, United States
Site 14

Houston, Texas, 77056, United States
Site 15

Indianapolis, Indiana, 46250, United States
Site 16

Murfreesboro, Tennessee, 37130, United States
Site 17

Aventura, Florida, 33180, United States
Site 18

Hackensack, New Jersey, 07601, United States
Site 19

West Jordan, Utah, 84095, United States
Site 20

Greensville, South Carolina, 29615, United States
Site 21

Vista, California, 92083, United States
Site 22

Brighton, Massachusetts, 02135, United States
Site 23

Rolling Meadows, Illinois, 60008, United States
Site 24

Englewood, Colorado, 80111, United States
Site 25

Brandon, Florida, 33511, United States
Site 26

Clarkston, Michigan, 48346, United States
Site 27

West Lafayette, Indiana, 47906, United States
Site 28

Phoenix, Arizona, 85018, United States
Site 29

Lynchburg, Virginia, 24501, United States
Site 30

Fort Smith, Arkansas, 72916, United States
Site 31

Boise, Idaho, 83704, United States
Site 32

New Albany, Indiana, 47150, United States
Site 33

Seattle, Washington, 98168, United States
Site 34

Sherman Oaks, California, 91403, United States
Site 35

Rogers, Arkansas, 72758, United States
Site 36

Birmingham, Alabama, 35203, United States
Site 37

Kew Gardens, New York, 11415, United States
Site 38

New York, New York, 10075, United States
Site 39

Boardman, Ohio, 44512, United States
Site 40

Bellaire, Texas, 77401, United States
Site 41

Baton Rouge, Louisiana, 70809, United States
Site 42

Hollywood, Florida, 33021, United States
Site 43

Atlanta, Georgia, 30329, United States
Site 44

Dallas, Texas, 75231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.